新型冠状病毒胃肠道损伤机制研究及胃饥饿素治疗展望  

Mechanism of gastrointestinal injury in COVID-19 and potential use of ghrelin therapy

作　　者：田家庚 刘欣培 张宝芹 张军鹏 孙光斌 李熳[2] Jia-Geng Tian;Xin-Pei Liu;Bao-Qin Zhang;Jun-Peng Zhang;Guang-Bin Sun;Man Li(Department of Gastroenterology,The Fifth Central Hospital of Tianjin,Tianjing 300450,China;Department of Gastroenterology,The Second Hospital of Tianjin Medical University,Tianjing 300211,China)

机构地区：[1]天津第五中心医院消化内科,天津市300450 [2]天津医科大学第二医院消化内科,天津市300211

出　　处：《世界华人消化杂志》2023年第11期431-437,共7页World Chinese Journal of Digestology

基　　金：天津市卫生健康委员会科技项目,No.TJWJ2021MS01。

摘　　要：呼吸系统和消化系统在新型冠状病感染中症状最为明显,严重威胁着患者的健康.其中食欲下降是消化系统中新型冠状病毒感染最常见的症状,同时是新型冠状病毒感染死亡率的重要预测因素.现大量患者在新型冠状病毒感染后出现食欲下降,且并未表现出明显的器质性疾病特征,目前没有药物能直接减轻症状.新型冠状病毒传染性高,致病性强,为降低重症、危重症患者的发病率,减少新型冠状病毒的住院率,了解其导致食欲下降的致病机制以及治疗新型冠状病毒感染相关型食欲下降至关重要.胃饥饿素是胃内分泌促进食欲的关键激素,具有抗炎,神经保护,抗抑郁等多重作用.本篇论文将阐述新型冠状病毒感染相关性食欲下降机制的研究进展,并介绍一种符合现研究机制的具有治疗潜力的药物-胃饥饿素.In Corona Virus Disease 2019(COVID-19),the most obvious symptoms occur in the respiratory and digestive systems,posing a serious threat to the health of patients.Decreased appetite is the most common digestive system symptom and is an important predictor of mortality.A large number of patients have decreased appetite after infection and do not show obvious organic disease characteristics.Currently,no drugs can directly alleviate such symptom.In order to reduce the number of severe and critically ill patients and decrease the hospitalization rate,it is very important to understand the pathogenic mechanism of appetite loss caused by COVID-19 and manage such symptom.Ghrelin is a key gastric hormone that has anti-inflammatory,neuroprotective,and antidepressant effects.In this paper,we will review the progress in the understanding of the mechanism of appetite loss associated with COVID-19,and introduce a potential therapeutic drug,ghrelin.

关 键 词：新型冠状病毒 食欲下降 胃饥饿素 神经炎症 胃肠肽 

分 类 号：R563.1[医药卫生—呼吸系统]